15-min delayed · Aug 25, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 7 firms covering Jasper Therapeutics Inc, 4 rate it Buy or better, 3 sit at Hold, and 0 rate it Sell or worse, a moderate buy consensus. The target range is very wide, $1.50 to $7.00 (about 4.7x), which points to deep disagreement over how to value the company rather than near-term timing. The average target of $3.38 sits 375% above the current $0.71. The rating mix has held broadly steady over recent months. On the fundamentals, the Street sees consensus EPS building from about $-0.75 next quarter toward $-2.56 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS7 ratings
Moderate Buy
Strong Buy00%
Buy457%
Hold343%
Sell00%
Strong Sell00%
Based on 7 analysts giving stock ratings to Jasper Therapeutics Inc.
As of Aug, 4 of 7 firms rate JSPR a Buy (3 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
JSPR EPS & revenue forecast
EPS · NEXT QUARTER
$-0.75
Range $-0.75 – $-0.75 · 1 analysts · +38% YoY
Next period, 1 analysts expect Jasper Therapeutics Inc to earn $-0.75 a share (range $-0.75 – $-0.75), versus $-0.54 a year earlier. Full-year consensus is $-2.41, growing to $-2.56 the year after.
REVENUE · NEXT QUARTER
$0
Range $0 – $0 · 1 analysts
Revenue is expected to reach $0 (range $0 – $0). Full-year consensus is $2.4M, rising to $0 next year.
Top analysts covering Jasper Therapeutics Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on JSPR.
#1
Silvan Tuerkcan
JMP Securities · Rank #30
Buy
$6.00+744.6% to target
Overall win rate
52%
+ Follow
#2
Leonid Timashev
RBC Capital · Rank #38
Hold
$3.00+322.3% to target
Overall win rate
47%
+ Follow
#3
PS
Pete Stavropoulos
Cantor Fitzgerald · Rank #274
Hold
No targeton JSPR
Overall win rate
35%
+ Follow
#4
Jay Olson
Oppenheimer · Rank #354
Buy
$65.00+9049.8% to target
Overall win rate
33%
+ Follow
#5
Emily Bodnar
HC Wainwright & Co. · Rank #396
Buy
$20.00+2715.3% to target
Overall win rate
23%
+ Follow
JSPR stock forecast FAQ
What is JSPR's average 12-month price target?+
The 4 analysts with a live target average $3.38 for Jasper Therapeutics Inc over the next 12 months, ranging from a $7.00 high to a $1.50 low.
Is JSPR stock a Buy, Sell or Hold right now?+
The current consensus is Moderate Buy. Of the 7 analyst ratings, 4 are Buy or Strong Buy, 3 are Hold, and 0 are Sell or Strong Sell.
What are the highest and lowest price targets for JSPR?+
The Street-high target is $7.00 (Evercore ISI Group), and the Street-low is $1.50 (UBS). The average of all 4 active targets is $3.38.
How many Wall Street analysts cover JSPR?+
7 analysts have an active rating on Jasper Therapeutics Inc, and 4 firms carry a live 12-month price target.
Who is the most accurate analyst covering JSPR?+
Among analysts who currently cover JSPR, Silvan Tuerkcan of JMP Securities has the strongest overall Quantellect track record (Rank #30). Their current call is Buy with a $6.00 target.
What is Jasper Therapeutics Inc's projected EPS for next quarter?+
The consensus estimate is $-0.75 per share (range $-0.75 – $-0.75) across 1 analysts. Full-year EPS is projected at $-2.41, rising to $-2.56 the following year.
How much revenue is Jasper Therapeutics Inc expected to report next quarter?+
Consensus revenue is $0 (range $0 – $0). Full-year revenue is projected at $2.4M, growing to $0 next year.
Have analysts been upgrading or downgrading JSPR lately?+
As of Aug, 4 of 7 firms rate JSPR a Buy (3 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their JSPR calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
